IONS has apetite for marketing the fruits of its research AKCA is its affiliate public company responsible for marketing some of IONS therapies. The relationship between AKCA and IONS is fairly byzantine. IONS has $1B in cash plus recurring revs EOY 2017 received $113mn from BIIB in 2017 for Spinraza royalties Expenses for FY/2017 were $397mn guided for $800mn cash EOY/18 Volanesorsen has an AdCom 5/10/18 and PDUFA 8/30/18 Inotersen has a PDUFA 7/6/18 AKCA will be responsiblie for marketing Volanesorsen and Inotersen. Both PFE & ALNY will likely soon be marketing competing compounds to Inotersen The long-term value of IONS is primarily in its pipeline, particularly in neural pipeline.